Also known as Deltasone and Meticorten.
Two‑year Vibrance‑MG data show maintained MG‑ADL and QMG improvements and steroid reductions in adolescents; HCP survey links fluctuating control to switches to IMAAVY.
Phase III CELESTIMO showed a statistically significant, clinically meaningful progression‑free survival benefit for Lunsumio plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory FL after ≥1 prior therapy.
The trial's sole U.S. primary endpoint—overall survival—did not reach statistical significance; additional results will be submitted for peer review.
sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
CHMP backs AKEEGA® for mHSPC with BRCA1/2 mutations, showing improved progression-free survival and manageable safety profile in Phase 3 AMPLITUDE study.
Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
FDA approves AKEEGA for BRCA2-mutated prostate cancer, reducing disease progression by 54% and delaying symptoms by 59% in clinical trials.
DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.
FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.
